Friday 6 November 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
214.29
6.29
+3.02%
Follow ILMN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 6 | 6 | 7 |
| 33.36% | 33.82% | 32.38% | 32.39% | ||
| 13.13% | 13.39% | 12.95% | 13.78% | ||
ROIC |
19.55% | 17.69% | 17.46% | 16.70% | |
Return on Tangible Assets |
34.51% | 44.27% | 41.23% | 34.29% | |
Average Days of Receivables |
71.77 | 61.32 | 62.07 | 59.36 | |
Free Cash Flow per Share |
6.01 | 6.37 | 6.17 | 7.00 | |
Free Cash Flow |
931.00 | 974.00 | 931.00 | 1,057.00 | |
Capital Expenditures |
(148.00) | (154.00) | (164.00) | (173.00) | |
| Other line items | |||||
Cash ROIC |
15.93% | 18.30% | 16.94% | 16.86% | |
Accounts Receivable Turnover |
5.47 | 6.11 | 6.13 | 6.19 | |
Accounts Payable Turnover |
6.39 | 6.99 | 7.02 | 6.35 | |
Inventory Turnover |
2.65 | 2.59 | 2.51 | 2.32 | |
Average Days of Payables |
59.47 | 53.58 | 55.60 | 60.33 | |
Days of Inventory on Hand |
139.76 | 150.18 | 152.04 | 166.98 | |
Tax Rate |
(0.22) | (0.20) | (0.19) | (0.15) | |
Research and Development Expense of Revenue |
22.27% | 21.74% | 21.37% | 21.49% | |
Selling, General and Administrative Expense of Revenue |
25.01% | 24.83% | 25.15% | 24.99% | |
Share Based Compensation of Revenue |
6.33% | 5.96% | 5.92% | 5.95% | |
Interest Coverage |
7.99 | 8.52 | 8.92 | 9.81 | |
Operating CF/Net income |
1.27 | 1.32 | 1.33 | 1.37 | |
Depreciation/Fixed assets |
0.36 | 0.36 | 0.37 | 0.38 | |
Capex/Depreciation |
(0.55) | (0.57) | (0.60) | (0.62) | |
Revenue per Share |
28.02 | 28.71 | 29.76 | 30.05 | |
Operating CF per Share |
6.96 | 7.37 | 7.25 | 8.15 | |
Capex per Share |
(0.95) | (1.01) | (1.09) | (1.15) | |
Capex to Sales |
0.03 | 0.04 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026